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Transendothelial migrationMesenchymal stem cells (MSCs) have the potential to migrate toward damaged tissues increasing tissue
regeneration. Interleukin-17 (IL-17) is a proinﬂammatory cytokine with pleiotropic effects associated with
many inﬂammatory diseases. Although IL-17 canmodulateMSC functions, its capacity to regulateMSCmigration
is not well elucidated so far. Here, we studied the role of IL-17 on peripheral blood (PB) derived MSC migration
and transmigration across endothelial cells. IL-17 increased PB-MSC migration in a wound healing assay as
well as cell mobilization from collagen gel. Concomitantly IL-17 induced the expression of urokinase type
plasminogen activator (uPA) without affecting matrix metalloproteinase expression. The incremented uPA
expression mediated the capacity of IL-17 to enhance PB-MSC migration in a ERK1,2 MAPK dependent way.
Also, IL-17 induced PB-MSC migration alongside with changes in cell polarization and uPA localization in cell
protrusions. Moreover, IL-17 increased PB-MSC adhesion to endothelial cells and transendothelial migration,
as well as increased the capacity of PB-MSC adhesion to ﬁbronectin, in an uPA-dependent fashion. Therefore,
our data suggested that IL-17 may act as chemotropic factor for PB-MSCs by incrementing cell motility and
uPA expression during inﬂammation development.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Cell migration is a complex process involving many both intra- and
extracellular components, as well as the signaling events linking them.
Due to their ability to preferentially migrate to sites of inﬂammation
and tissue injury, and their immunomodulatory properties, mesenchy-
mal stem cells (MSCs) have great potential for tissue regeneration and
cellular therapy [1]. However, the molecular signals that guide MSCs
to target tissues remain to be fully elucidated. One of the most remark-
able, but least understoodﬁndings is the ability ofMSCs tomigrate from
bone marrow or peripheral blood into damaged tissues to promote
regeneration [2,3]. Although MSCs can be recruited to damaged or
inﬂamed tissue by inﬂammatory cytokines [1], the molecular and
cellular mechanisms mediating the recruitment of MSCs are not well
understood so far.
Various inﬂammatory and autoimmune diseases, such as rheuma-
toid arthritis, psoriasis or inﬂammatory myopathies, include inﬁltrationearch, University of Belgrade,
788; fax: +381 11 2643 691.
ez).of Th17 cells into the tissue and high production of Interleukin-17 cyto-
kines (IL-17) [4]. IL-17A, a founding member of the cytokine family has
been known to regulate the pro-inﬂammatory responses by acting on
different stromal cells, stimulating them to secrete other soluble and
membrane-bound factors, among which are IL-6, G-CSF, GM-CSF, SCF,
and NO. In addition, stromal cells, including bone marrow (BM) MSCs,
express high levels of IL-17 receptor A (IL-17RA) and IL-17 has been
shown to affect the proliferation and differentiation of MSCs [5,6].
Also, IL-17 affects MSC differentiation by inhibiting adipogenesis and
myogenesis while promoting osteogenesis [7,8]. Nevertheless, the
roles which IL-17 can have in MSC physiology are under research, and
little is known about its involvement in MSC migration and homing to
inﬂamed tissue.
In response to tissue damageMSCs aremobilized frombonemarrow
to the blood circulation and “invade” the target tissue [1,2]. A key re-
quirement for cells to reach distant target sites is their ability to traverse
the protein ﬁbers of the extracellular matrix (ECM) which are present
between cells of all tissue types [9]. To overcome these matrix barriers,
migrating cells require speciﬁc proteolytic enzymes. One of the most
important enzymes which enables cell migration is urokinase plasmin-
ogen activator (uPA). uPA is a proteolytic enzyme which belongs to the
group of trypsin-like enzymes. uPAmediates the proteolytic cleavage of
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spectrum of activity, is able to directly break down the components of
the ECM, such as ﬁbrin, ﬁbronectin, laminin, collagen IV and the protein
backbone of the proteoglycans [11]. Biosynthesis and activity of uPA
are associated with the invasive capacity of various cell types such as
leukocytes, endothelial cells, and metastasizing tumor cells. In addition
to traversing the ECM, during their migration through the body, MSCs
need to pass through the endothelium in order to enter the target tissue.
Regarding their mobilization to the sites of inﬂammation, MSCs proba-
bly hold properties similar to immune cells. Hence, the well described
transendothelial migration of leukocytes can serve as a starting model
for MSC transendothelial migration [12]. Certain proinﬂammatory
cytokines, such as IL-1β and TNF-α are known to increase themigratory
and adhesion capacity of MSCs in vivo, by up-regulating adhesive
proteins and receptors for some chemokines in these cells [1]. Although
IL-17 is present in damaged or inﬂamed tissues and uPA recently
has been implicated in migration and tropism to tumor microenviron-
ment [13–15], the capacity of IL-17 to induce peripheral blood MSC
(PB-MSC) migration and endothelium transmigration, as well as the
involvement of uPA in these processes, was not elucidated so far. There-
fore, in this work, we have examined whether IL-17, as a proinﬂamma-
tory cytokine, is able to modulate the expression of uPA in PB-MSCs,
and its importance in PB-MSC motility, endothelial cell adhesion and
transendothelial migration.
2. Material and methods
2.1. Cell culture
The PB-MSC isolation was previously described [16]. Brieﬂy, periph-
eral bloodmononuclear cells (PBMC)were isolated from the peripheral
blood of healthy donors by density gradient centrifugation on lympho-
cyte separation media (PAA Laboratories, Linz, Austria), and plated in
cell culture ﬂasks in growth medium (GM) consisting of 10% fetal bo-
vine serum (FBS) and 100 units/ml Penicillin/Streptomycin (both from
PAA Laboratories) in high glucose Dulbecco's Modiﬁed Eagle's Medium
(DMEM, Sigma-Aldrich, St Luis, MO, USA) and cultured in a humidiﬁed
atmosphere at 37 °C with 5% CO2. The medium was replaced twice a
week and nonadherent cells were discarded. Adherent, ﬁbroblast-like
cells were detached and seeded in a new ﬂask in GM. Following
the ﬁrst conﬂuence, cells were passaged regularly, and after three pas-
sages a homogenous cell culture was obtained. PB-MSCs obtained
displayed a multipotent capacity of mesenchymal differentiation,
since under appropriate conditions they differentiated to osteogenic,
chondrogenic, adipogenic, and myogenic lineages. In addition, they
were fully characterized and displayed a normal karyotype [16].
Humanmicrovascular endothelial cells (HMEC cell line) were kindly
provided by Dr. C. Bernabeu (CIB, CSIC, Spain). Cells grown in 0.2%
gelatin-coated ﬂasks in endothelial cell (EC) medium consisting of 50%
DMEM, 50%Ham's F12 (Sigma-Aldrich), 1 μMhydrocortisone (Galenika,
Belgrade, Serbia), 20 ng/ml EGF (R&D Systems, Minneapolis, MN, USA)
and 5 μl/ml ECGS (Sigma-Aldrich). Myoblast C2C12 cell line was
purchased from American Type Culture Collection (ATCC, CRL-1772)
and cultured in DMEM supplemented with 10% fetal. The prostatic ade-
nocarcinomaderived PC-3 cell linewas obtained fromATCC (CRL-1435)
and grown in Hams F12:DMEM (1:1) supplemented with 10% FBS.
2.2. Antibodies and reagents
Anti uPA, IL-17 and IL-17R rabbit antibodies (sc-14019, sc-7927
and sc-30175 respectively) were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Antibodies against MT1-MMP, pERK1,2, ERK1,2,
pp38 and p38 were purchased from R&D Systems. For immunoﬂuores-
cence analysis, anti α-tubulin, anti γ-tubulin, anti-mouse-FITC second-
ary antibody and DAPI were from Sigma-Aldrich. For F-actin staining,
phalloidin coupled to TRITC (Sigma-Aldrich) was used. Recombinanthuman IL-17 and human recombinant TGF-beta were provided by
R&D Systems. Epsilon aminocaproic acid (EACA) and doxycycline
were from Sigma-Aldrich. 12-O-tetradecanoylphorbol-13-acetate
(TPA), p38 inhibitor SB203580 and MEK1,2 inhibitor PD98059 were
obtained from Calbiochem (Darmstadt, Germany), while uPA inhib-
itor, BC11 hydrobromide was purchased from Tocris Bioscience
(Bristol, UK). Anti-uPA mouse Mab, SAM-3, was kindly provided by
Dr. F. Castellino (University of Notre Dame, Indiana).2.3. PBMSC immunophenotyping
To phenotype cell-surface antigens, third-passage cells were
stained with ﬂuorescein isothiocyannate (FITC)- or phycoerythrin
(PE)-conjugated antibodies speciﬁc for the following human antigens
CD90-PE, CD44-PE, CD73, CD11b (Biosource), CD45-FITC (R&DSystem),
and CD105-PE (Invitrogen). Stained cells were analyzed using CyFlow
CL (Partec, Munster, Germany). For each sample, at least 10,000 events
were recorded.2.4. Wound healing and invasion assays
Cell migration was analyzed by an in vitro wound healing assay.
Brieﬂy, 5 × 104 cells/well were seeded in 24 well plates and allowed
to grow until conﬂuence, when a scratch wound in the monolayer
was made by a 200 μl pipette tip. After the cells were washed three
times with PBS, they were allowed to migrate for additional 24 h in
GMwith the treatments indicated in Results. After themigration period,
cells were ﬁxed with ice-cold methanol and stained with 0.1% crystal
violet. Cell migration into the scratch area was photographed using
an inverted light microscope and quantiﬁed by TScratch software
(Computational Science and Engineering Laboratory, Swiss Federal
Institute of Technology, ETH Zurich, Zurich, Switzerland).
The migration capacity of PB-MSC was also evaluated in a Boyden
chamber-based cell migration assay (Costar, Cambridge MA) with
8.0 μm-pore polycarbonate ﬁlters (Collaborative Research, Bedford,
MA). Brieﬂy, PB-MSCs were labeled with PKH26, according to
manufacturer's instructions and seeded in the upper chamber (105
cells per transwell) in 100 μl of growth medium. Growth medium (0.
5 ml), with or without IL-17, as chemoattractant factor, and the
indicated inhibitors, were added in the lower chamber. After 16 h,
cells from the upper compartment were cleaned with a cotton swab
to remove the nonmigrating cells. Cells attached to the bottom of
transwells were ﬁxed by immersing the transwells into 3.7% formal-
dehyde in PBS. After washing, transwells were turned upside down,
mounted with a cover slip and cells were observed using an epi-
ﬂuorescence microscope. Red labeled cells from each sample were
counted using ImageJ software in eight randomﬁelds per transwell insert.2.5. Cell mobilization assay
Collagen was prepared as described previously [17]. Brieﬂy, type I
collagen was extracted from rat tail tendons in 0.2% acetic acid and 4.4
mg/ml solution was obtained. This solution was subsequently mixed
with 0.34 N NaOH and 10 times concentrated DMEM in an 8:1:1 ratio
and stored at 4 °C to initiate the gelling process. For cell mobilization
assay, 1.2 × 106 PB-MSCs were embedded in 600 μl of collagen I (2.2
mg/ml) and four 25 μl drops were added per well in a 6 well plate.
After 1 h of incubation in a humidiﬁed atmosphere at 37 °C with
5% CO2, the cell–collagen drops gelled and 2 ml of GM with 0, 25 or
50 ng/ml IL-17 was added to each well. After a 5-day culture, cell
mobilization from the collagen plugs into the surrounding plastic sur-
facewasmonitored by phase-contrast microscopy. For the experiments
using inhibitors, PD98059 (25 μM) or BC11 hydrobromide (50 μM)was
added to GM 30 min prior to the addition of rhIL-17.
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The proliferation rate of PB-MSCs was analyzed by MTT assay.
Brieﬂy, 5 × 103 cells/well were seeded in 96 well plates in GM. The
following day rhIL-17 (0, 25 and 50 ng/ml) was added to GM and
cells were incubated for additional 3 days. After this period, 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MMT, Sigma-
Aldrich) was added to each well at 0.5 mg/ml and cells were incubated
for additional 2 h. The culture medium was then discarded and the cell-
precipitated formazan crystals were dissolved in Isopropanol:DMSO
(3:2). The absorbance was read at 540 nm [8].2.7. Western blot assay
Cells were lysed for 30min at 4 °C in 200 μl of lysis buffer (1% NP-40,
150 mM NaCl, 50 mM Tris pH 7.5, with 1 mM Na3VO4 and protease
inhibitors). Equal amounts of proteins of each extract were separated
by SDS-PAGE and transferred to Hybond ECL nitrocellulose membranes
(AppliChem, Darmstadt, Germany). Themembraneswere blocked in 4%
non-fat milk in TBS buffer containing 0.05% Tween 20. The membranes
were then incubated with primary, and subsequently with horseradish
peroxidase-conjugated secondary antibodies. Speciﬁc protein bands
were visualized using the ECL reagent from Serva, Heidelberg,IL-17R
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(untreated cells) by t-test: *p b 0.05 and **p b 0.005. (B) Cell migration by Boyden chamber-based cell migration assay. PKH26 labeled cells were seeded in the upper
chamber and IL-17 (50 ng/ml) was added in lower chamber. After 16 h cells crossing to the bottom face of membrane were ﬁxed and examined by an epi-ﬂuorescence
microscope. Ten random ﬁelds per sample were photographed and cells counted. Bars represent means ± SEM. Signiﬁcant difference from the control (untreated cells)
by t-test: *p b 0.05 and **p b 0.005. (C) PB-MSC mobilization from collagen gel. PB-MSCs embedded into collagen drops were treated with or without IL-17 as indicated
during 5 days. After ﬁxing and staining the samples were photographed. Drop magniﬁcation ×20, scale bars 1 mm, and cell magniﬁcation ×100. Results are representative
from at least 3 independent experiments performed in triplicate. (D)Migration of PB-MSC analyzed by scratch assay. A scratchwasmade in the conﬂuentmonolayer of cells, and cells were
cultured in the presence of or absence of IL-17 (50 ng/ml) with orwithout anti-IL-17 antibody (ab, 4 μg/ml). The recolonization of the scratch by adjoining cells was documented after 24 h;
bars representmeans±SEMpercentageof the scratch area coveredwithmigrating cells.Magniﬁcation×100 and scale bars 100 μm. Signiﬁcant difference from the control (untreated cells)
by t-test: *p b 0.05 and **p b 0.005. (E) Cell migration by Boyden chamber-based cell migration assay. PKH26 labeled cells were seeded in the upper chamber, IL-17 (50 ng/ml), with or
without anti-IL-17 antibody (ab, 4 μg/ml), was added in lower chamber. After 16 h cells crossing to the bottom face of membrane were ﬁxed and examined by an epi-ﬂuorescence micro-
scope. Ten random ﬁelds per sample were photographed and cells counted. Bars represent means ± SEM. Signiﬁcant difference from the control (untreated cells) by t-test: **p b 0.005.
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5% acetic acid until transparent proteolytic bands were observed. As a
positive control for MMP-9 in zymography assay the CM from PC-3
cells treated with 100 ng/ml of TPA for 24 h was used. The uPA
and MMP bands were quantiﬁed by densitometry, using NIH-ImageJ
software [16].2.9. RT-PCR
After speciﬁc cell treatments, indicated in Results, total RNA was
obtained using TRIzol (Applichem) and complementary DNA was
generated by the RevertAid™ H Minus First Strand cDNA Synthesis
Kit (Thermo Scientiﬁc,Waltham,MA, USA), using oligo (dT) as a primer.
435J. Krstić et al. / Biochimica et Biophysica Acta 1853 (2015) 431–444PCR conditions and the primer set (Invitrogen, Carlsbad, CA, USA) used
are described in Supplementary Table. PCR products were obtained
after between 25 and 35 cycles of ampliﬁcation for individual genes
with indicated annealing temperature. Amplicons were resolved in
1.5% agarose gel and stained with ethidium bromide. GAPDH was am-
pliﬁed as a control for the amount of cDNA present in each sample.
The intensity of the bands was quantiﬁed using NIH-ImageJ software.
2.10. PB-MSC polarization during migration
Immunoﬂuorescence assay was used to detect beta-actin; alpha-
and gamma-tubulin in migrating PB-MSCs. Brieﬂy, 105 cells were
seeded per rounded cover slip in GM and allowed to grow until conﬂu-
ence, when a scratch wound in the monolayer was made by a 200 μl
pipette tip. After the cells were washed three times with PBS, they
were allowed to migrate for additional 6 h in GM with or without
IL-17 (50 ng/ml), PD98059 (25 μM), or BC11 (50 μM), as indicated in
Results. After being ﬁxedwith 4% formaldehyde in PBS, cell monolayers
were incubated with speciﬁc primary antibodies, followed by incuba-
tion with corresponding ﬂuorescently labeled secondary antibodies
and 1 μg/ml DAPI. After mounting, the samples were examined and
photographed using an epi-ﬂuorescence microscope [18].
2.11. Adhesion of PB-MSCs to endothelial cells
HMECs (105 cells/cover slip) were seeded over 0.2% gelatin-coated
round glass coverslips and incubated for 48 h in a humidiﬁed atmo-
sphere at 37 °C with 5% CO2, until reaching conﬂuence. Cells were
then stained with DAPI (5 μg/ml) for 15 min at room temperature
and washed twice with PBS. At the same time when seeding
HMECs, 4 × 105 PB-MSCs were seeded per well in a 6 well plate.
After they were incubated over night in a humidiﬁed atmosphere
at 37 °C with 5% CO2, PB-MSCs were treated with 0 or 50 ng/ml IL-
17 for 24 h. Following the treatment, PB-MSCs were detached with
1 mM EDTA and labeled using PKH26 Red Fluorescent Cell Linker
Kit for General Cell Membrane Labeling (Sigma-Aldrich), according to
manufacturer's instructions. Labeled PB-MSCs were then seeded
over HMECs (105 cells/cover slip) and incubated in a humidiﬁed atmo-
sphere at 37 °C with 5% CO2 for 30 min. After incubation, cover slips
were washed twice with PBS; cells were ﬁxed with 3.7% formaldehyde
in PBS and mounted. The samples were examined and photographed
using an epi-ﬂuorescence microscope. Eight to ten random ﬁelds from
each cover slip were photographed and red labeled cells were counted
using ImageJ software. To analyze whether IL-17 affects adhesion of
PB-MSCs by acting on endothelial cells, the same experiment where
HMECs were treated with 0 or 50 ng/ml IL-17 instead of PB-MSCs
was conducted.
2.12. Transendothelial migration of PB-MSCs
HMECs were seeded in 24 well plate transwell inserts (Corning,
Tewksbury, MA, USA), 6 × 105 cells per transwell, in EC medium and
incubated in a humidiﬁed atmosphere at 37 °C with 5% CO2 overnight.
PB-MSCs were labeled with PKH26, according to manufacturer's
instructions and seeded over HMECs (105 cells per transwell) in 100 μl
EC mediumwith or without BC11 (50 μM). Under the transwell inserts,
0.5ml ECmediumwith 0 and 50 ng/ml IL-17 in the presence or absence
of BC11 (50 μM) was added in the bottom chamber. Cells were then
incubated in a humidiﬁed atmosphere at 37 °C with 5% CO2 for 30 h
to allow transmigration of PB-MSCs through the HMEC monolayer.
The bottom part of transwell inserts was then washed with PBS three
times and the top part was cleaned with a cotton swab to remove the
nonmigrating cells. Cells attached to the bottom of transwells were
ﬁxed by immersing the transwells into 3.7% formaldehyde in PBS.
After washing, transwells were turned upside down, mounted with
a cover slip and cells were observed using an epi-ﬂuorescencemicroscope. Red labeled cells in ten random ﬁelds from each sample
were counted using ImageJ software.
2.13. Fibronectin cell adhesion assay
For the adhesion assay, 24 well plates were coated with 10 μg/ml of
ﬁbronectin (Sigma-Aldrich, St Luis, MO, USA) for 24 h at 4 °C and
blocked with 1% BSA in PBS at 37 °C for 1 h. PB-MSCs were treated
with IL-17 (50 ng/ml) for 24 h, detached with 1 mM EDTA in PBS,
resuspended in DMEM containing 0.5% FBS and pretreated with
SAM-3 anti-uPA antibody (10 μg/ml) or BC11 (50 μM) in a humidiﬁed
atmosphere at 37 °C with 5% CO2 for 1 h. Then, 105 cells were seeded
in ﬁbronectin coated plates and allowed to adhere for 30 min. The
wells blocked with BSA/PBS only were used as a control for basal adhe-
sion. After the incubation time, non-adherent cells were discarded by
washing the wells three times with PBS. MTT (0.5 mg/ml) was added
to adherent cells which were cultured in GM for additional 2 h. The
precipitated formazan was dissolved with Isopropanol:DMSO (3:2)
and the absorbance was read at 540 nm.
2.14. Statistical analysis
Data are given as means (±SEM) from at least three independent
experiments. Student's t test was performed to evaluate the probability
of signiﬁcant differences among the samples with p b 0.05 (*) and
p b 0.005 (**) considered signiﬁcant.
3. Results
3.1. Immunophenotyping and IL-17 receptor expression in PB-MSCs
According to criteria proposed by theMesenchymal and Tissue Stem
Cell Committee of the International Society for Cellular Therapy [19]
the mesenchymal phenotype of PB-MSCs was analyzed by ﬂow
cytometry. PB-MSCs isolated by plastic adhesion were subjected to
immunophenotyping to MSC speciﬁc cell surface antigen expression.
More than 90% of cells were positive for CD90, CD73, and CD105; 77%
for CD44 and low level for CD45 and CD11b expressions (Fig. 1A). In
addition, cells were able to differentiate into three-lineages (osteo-
blasts, adipocytes and chondrocytes) under standard in vitro condi-
tion (data not shown). Next, we elucidated whether PB-MSC
express IL-17 receptor by subjecting cells to Western blot analysis.
A duplicate determination showed 120 kDa IL-17R protein expres-
sion similar to IL-17R expression in C2C12 cells which we previously
reported [7] and used here as positive control (Fig. 1B). IL-17R ex-
pression also was conﬁrmed by RTPCR assay using peripheral blood
mononuclear cells (PBMC) as positive control and PCR reaction in
the absence of cDNA as negative control (Fig. 1C).
3.2. IL-17 enhances PB-MSC migration
During injury and inﬂammation recruitment of MSCs is triggered by
speciﬁc signals present at the site of damage, and cells are improving
their migratory capacity to move toward damaged tissues. IL-17 is
known as one of the pro-inﬂammatory cytokines whose levels are
increased during inﬂammation [20], therefore, we analyzed whether
IL-17 modulates PB-MSC migration by wound healing assay. The treat-
ment of PB-MSCs with two different concentrations of IL-17 (25 and
50 ng/ml) for 24 h greatly enhanced the capacity of cells to migrate
into the wound in comparison with the cells incubated in the absence
of the cytokine (Fig. 2A). IL-17 at higher concentration induced almost
a complete scratch closure (about 90%) during the experimental time
period. To support the capability of IL-17 to induce cell motility, a che-
motaxis Boyden chamber-based cell migration assay was performed.
PB-MSCs responded to IL-17 (25 and 50 ng/ml) in the lower chamber,
by incrementing their migration through the 8 μm pores to the bottom
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control cells after 16 h of experimental time period (Fig. 2B). Next, we
determined the capacity of PB-MSCs tomobilize from type I collagenhy-
drogel drops. Therefore, PB-MSCs were embedded within 3D type I col-
lagen drop gels, and mobilization capacities were determined in the
absence or presence of IL-17. IL-17 treatment, at both 25 and
50 ng/ml, enhanced cell exit from collagen gels compared with control
cells (Fig. 2C). Interestingly, the mobilization of MSCs from collagen
showed a collective migration more than individual cell migration.(A)
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MSCs were treated with same concentrations of IL-17 as in the wound
healing assay for 3 days and cell proliferation was analyzed by MTT
assay. The results showed that IL-17 does not modify cell proliferation
(Fig. S1), suggesting that the cytokine acts as a motility factor for
MSCs, and that closing of the scratch wound and collagen gel mobiliza-
tion aremainly due to IL-17 stimulating the cellmigration andnot by in-
creasing the cell number. In order to determine the direct role of IL-17
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437J. Krstić et al. / Biochimica et Biophysica Acta 1853 (2015) 431–444performed. By using an antibody against IL-17 (4ug/ml), reduction of
PB-MSC responses to IL-17 both in migration and invasion assays
were observed (Fig. 2D and E), suggesting that IL-17 ligand is the
primary factor that induced the incremented cell motility in our
experimental conditions.
3.3. IL-17 induces uPA production in PB-MSCs
One of the key events involved in cell migration is the production
of extracellular proteinases which allows cells to modify the ECM or
directly enhance the motility of cells [9]. Further experiments aimed
to determine whether IL-17 modulates the capacity of PB-MSCs to
produce uPA. Cells were incubated in the presence of 0, 25 and
50 ng/ml IL-17 in serum-free culture medium for 24 h and the produc-
tion of uPAwas determined byWestern blot and zymography.Western
blot analysis allowed the determination of cell-associated uPA, while
the amount of uPA secreted into the CM was determined by
zymography. IL-17, both at 25 and 50 ng/ml, signiﬁcantly increased
the production of uPA in PB-MSCs. uPAproduction after IL-17 treatment
was also increased at transcriptional level, as determined by RT-PCR
analysis (Fig. 3A). uPA produced by PC3 cells was used as a positive
control in order to compare and determine the correct MW sizeIL-17 -
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Fig. 4. IL-17-induced PB-MSCmigration and collagen-mobilization are uPA dependent. (A) PB-M
the presence or absence of uPA inhibitor BC11 (50 μM), uPA blocking antibody (5 μg/ml) or doxy
cells. Signiﬁcant difference from the control (indicated by arrow): *p b 0.05. (B) PB-MSCs embe
the presence or absence of 50 μMBC11. After ﬁxing and staining the sampleswere photographe
experiments performed in triplicate.of human uPA produced by PB-MSC (Fig. 3B). uPA mRNA from
PC3 cells was also used as positive control in order to compare and
determine the correct size of corresponding PCR products (Fig. 3C).
The IL-17-induced enhancement in uPA transcript expression in
PB-MSCs was rapid, with a noticeable increment visible 2 h after
treatment, reaching two-fold expression compared to the control
in all the following time points tested up to 24 h, which implied
that IL-17 directly modulates uPA expression in PB-MSCs (Fig. 3D).
Interestingly, IL-17 did not induce the expression of PAI-1, the phys-
iological inhibitor of uPA, as determined by RT-PCR, using PC-3 cells
treated with TGF-beta (10 ng/ml) for 24 h as a positive control
(Fig. S2).
3.4. Expression of MMPs in PB-MSCs is IL-17 independent
Besides uPA, stem cells are capable of expressing matrix
metalloproteinases (MMPs) which are also implicated in MSC
migration [21]. Further experiments were performed in order to
determine whether IL-17 modulates the expression of MMPs in
PB-MSCs. Zymography analysis indicated that PB-MSCs mainly secrete
MMP2 and its expressionwas notmodiﬁed by IL-17 treatment. However,
no activity corresponding to MMP-9 was noticed. Conditioned medium+BC11
+
C
- + - +
- - - -
+ + - -
- - + +
SCs were subjected to wound healing assay under IL-17 treatment (50 ng/ml) for 24 h in
cycline (1 μg/ml). Bars represent the percentage of the scratch area coveredwithmigrating
dded into collagen drops were treatedwith or without IL-17, as indicated, during 5 days in
d. Collagen dropmagniﬁcation ×40. Results are representative from at least 3 independent
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Additionally, the expression of MT1-MMP/MMP14, known to be
expressed in MSCs [21] was also not modulated by IL-17 treatment,
as determined by Western blot assay. The zymography results were
conﬁrmed by RT-PCR results, showing that the expression of the
MMP2 and MT1-MMP/MMP14 mRNAs were not modiﬁed by IL-17,
as well as that MMP9 mRNA transcript was not observed in any
condition and using PC-3 cells treated with TPA (100 ng/ml) for 24
h as a positive control (Fig. S2B).
3.5. uPA mediates the IL-17- induced PB-MSC migration
The implication of uPA in IL-17-induced cell migration was ana-
lyzed by using BC11 hydrobromide, a selective uPA inhibitor, as*
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determined bywound healing assay. Cells were treated for 24 hwith 0 or 50 ng/ml of IL-17 in th
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magniﬁcation ×40. (D) ERK1,2 mediates IL-17-induced uPA expression. PB-MSCs were incuba
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normalize uPA activity and expression. MMP2 secretion determined by zymography was used
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WB. Results are representative as means ± SEM of three independent experiments performedwell as the anti-uPA blocking antibody. As shown in Fig. 4A, BC11
and anti-uPA antibody inhibited both basal and IL-17-induced cell
migration. To further support the results suggesting that IL-17 in-
creases PB-MSC migration by enhancing uPA production, we used a
broad MMP inhibitor, doxycycline (1 μg/ml). Although doxycycline
reduced the basal level of cell migration, its effect on IL-17-induced
migration of PB-MSCs was not signiﬁcant. This result suggested
that the enhancement of uPA can overcome the inhibition of
MMPs, making this extracellular proteinase responsible for the en-
hancement of PB-MSC migration by IL-17. Next, we determined the
effect of uPA inhibition on collagen gel mobilization (Fig. 4B). The ad-
dition of BC11 provoked a strong inhibition of cell mobilization from
collagen drops either in basal or in IL-17 treatment conditions. In ad-
dition, epsilon-aminocaproic acid (EACA), which blocks the high-IL-17 - +
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lytic uPA effector) [22], inhibited both IL-17-induced cell migration and
collagen mobilization (Fig. S3).3.6. ERK1,2 mediates IL-17-stimulated cell migration and uPA expression
Subsequent experiments were addressed to determine the in-
volvement of intracellular signaling pathways in IL-17-induced cell
migration and uPA expression in PB-MSCs. IL-17 (50 ng/ml) pro-
voked a rapid activation of ERK1,2, which was noticeable 5 min
after treatment, reaching maximum at 30 min and subsequently de-
creasing to basal level (Fig. 5A). To determine the involvement of
ERK1,2 on the IL-17-stimulated migration of PB-MSCs, cells were
treated with MAPK inhibitors in the absence or presence of IL-17
and both migration capacity and collagen gel mobilization were de-
termined. As shown in Figs. 5B and 5C, PD98059 inhibited the basal
level of migration capacity of PB-MSCs and strongly reduced IL-17-
stimulated wound closure and collagen gel mobilization. Since
ERK1,2 signaling appeared to be involved in the stimulation of cell
migration by IL-17, we next aimed to determine the involvement of
this signaling pathway in the IL-17-enhanced uPA expression. Cells
were treated or not with PD98059 for 30 min prior to adding IL-17
(0 or 50 ng/ml) into the serum-free culture media. After 24 h of incu-
bation, we analyzed the uPA production by Western blot and
zymography assays. α-Tubulin was used as loading control in West-
ern blot assay, and MMP2 production was also determined by
zymography as a loading control. The presence of PD98059, strongly
reduced the IL-17-enhanced uPA expression in PB-MSCs, as well as
the amount of uPA secreted into CM, at the same time not affecting
MMP2 secretion (Fig. 5D). Conversely, although IL-17 was capable
to activate p38 in PB-MSCs, the p38 inhibition by SB203580, neither
inhibited the IL-17-induced cell migration nor IL-17-enhanced uPA
expression (Fig. S4).3.7. IL-17 enhances PB-MSC migration by increasing cell polarity
Actin and tubulin cytoskeleton reorganization are among the
main mechanisms involved in cell migration [23]. During migration,
cells become polarized, and therefore it is possible to distinguish two
well-differentiated poles, the leading edge and the trailing edge. The
microtubule organizing center (MTOC) consisting of γ-tubulin is ori-
ented toward the “movement path” of the cell. We further investi-
gated whether IL-17 can modulate the cytoskeleton organization
and cell polarization during migration in the wound healing assay.
Firstly, the “wounded” monolayer of PB-MSCs was treated for 6 h
with or without IL-17. Prior to IL-17 addition, cells were treated or
not with PD98059 or BC11 for 30 min. When compared to untreated
cells, PB-MSCs in the presence of IL-17 reorganized their F-actin cy-
toskeleton, orientating the ﬁbers into the scratch (Fig. 6A). Also,
the cells positioned in the wound edge showed polarization of
MTOC, immune-labeled with anti-γ-tubulin, which was mainly lo-
calized between the nucleus and the edge of cell protrusions. When
cells were pre-treated with the MEK1,2 inhibitor, γ-tubulin showed
a random position and F-actin was observed in the position parallel
to the wound edge, indicating that PB-MSCs lost their motile pheno-
type in the presence of the inhibitor. When cells were treated with
uPA inhibitor BC11, although cell migration was inhibited and F-
actin showed a cortical pattern in wound edge, the effect on IL-17-
induced cell polarization was weaker compared with ERK1,2 inhibi-
tion. In addition, uPA is localized in PB-MSC cell surface showing a
punctuated pattern as was shown by immunoﬂuorescence assay.
The IL-17-induced cell movement was accompanied with uPA local-
ization in cell protrusion in the edge of wound (Fig. 6B–b), which
was strongly inhibited by either ERK1,2 or uPA inhibition.3.8. IL-17 enhances adhesion of PB-MSCs to endothelial cells,
trans-endothelial migration and ﬁbronectin adhesion
In response to signals from damaged tissues, circulating mesenchy-
mal stem cells have tomigrate across endothelium [24]. One of the ﬁrst
steps is the PB-MSC adhesion to endothelium and their subsequent di-
apedesis across the endothelial monolayer [24]. Therefore to determine
whether IL-17 regulates PB-MSC adhesion to endothelial cell monolay-
er, we pre-treated either MSC or EC monolayer with IL-17 for 24 h and
performed cell–cell adhesion assay. As shown in Fig. 7A, the IL-17 treat-
ment of PB-MSCs increased the adhesion capacity to EC monolayer;
similarly the treatment of ECs with IL-17 also increased the capacity of
PB-MSCs to contact with ECs, suggesting that IL-17 regulates the func-
tionality of both cell types to modulate MSC–EC adhesion.
After MSC cell–cell interaction with ECs, cells are integrated and
ﬁnally pass and leave endothelial layer barrier [25]. Thus, we next
investigated whether IL-17 regulates PB-MSC transendothelial
migration, as well as the implication of uPA in this process. PKH-26
labeled PB-MSCs were subjected to migrate across endothelial
monolayer in the presence or absence of uPA inhibitor BC11, while
IL-17 was added in the bottom chamber as chemoattractant factor.
The PB-MSCs underwent an enhanced transmigration capacity in
response to IL-17 (Fig. 7B), whereas uPA inhibition disabled IL-17
increasing PB-MSC transendothelial migration and also affected
basal capacity of cells to move across EC monolayer. This ﬁnding
indicates that IL-17 enhances cell–cell adhesion processes concomi-
tantly with increasing PB-MSC transendothelial capacity in uPA
activity-dependent way.
To migrate toward damaged or tissue under inﬂammation MSCs
have to interact with sub-endothelial extracellular matrix to move
across the basement membrane [26]. Therefore, we next focused on
ﬁbronectin, one of the components of sub-endothelial basement mem-
brane implicated in endothelial permeability [27,28]. To determine the
capacity of ECs to produce and accumulate ﬁbronectin we performed
an immunoﬂuorescence assay. Non-permeabilized ﬁxed EC monolayer
showed ﬁbronectin expression which mainly accumulates over cell
membrane showing both punctuated and “ﬁbrillar” pattern (Fig. 7C).
Subsequently, to determinewhether IL-17modulates PB-MSC adhesion
to ﬁbronectin, an adhesion assay using ﬁbronectin coated plates was
performed (Fig. 7D). The pre-treatment of PB-MSCs with IL-17 in-
creased the ﬁbronectin adhesion cell capacity compared with control
cells; meanwhile the presence of uPA inhibitor BC11 reduced IL-17-
increased PB-MSC adhesion to ﬁbronectin. Moreover, using an anti-
uPA blocking antibody, which inhibits both uPA binding to cell surface
receptor and its activity, dramatically inhibited the cell adhesion to
ﬁbronectin under IL-17 stimulus, with value lower than basal cell
adhesion capacity. Intriguingly, neither BC11 nor anti-uPA antibody
reduced the capacity of cells to interact with ﬁbronectin; suggesting
that basal cell-ﬁbronectin adhesion may be independent of uPA.4. Discussion
During injuries and chronic pathological vascular changes mesen-
chymal stem cells are mobilized mainly from bone marrow to the
blood circulation.MSCsmigrate through endothelium and are recruited
to the affected tissue, where they can regulate inﬂammatory responses,
andwhen cued by the appropriatemicroenvironmentmay differentiate
into tissue speciﬁc cells [23,29]. Also during tissue damage, cells from
innate and adaptive immune system are recruited and participate in in-
ﬂammatory response and tissue regeneration. Indeed, by production of
cytokines and growth factors immune cells can inducemobilization, re-
cruitment and regenerative capacity of MSCs [30,31]. Recently a subset
of CD4+ T cells, the Th17 cells that secrete cytokines IL-17A and IL-17F
and express surface IL-23 receptor (IL-23R), have been shown to play
signiﬁcant roles in inﬂammation and inﬂammatory diseases [32].
440 J. Krstić et al. / Biochimica et Biophysica Acta 1853 (2015) 431–444Here, we have investigated the role of IL-17A in peripheral blood
mesenchymal stem cell migration and endothelial transmigration.
PB-MSCs used in this study exhibited the main characteristic of mesen-
chymal stem cells, such as plastic adhesion and speciﬁc surface antigen
expression of the main mesenchymal cluster of differentiation such as
CD90, CD105, CD73 and CD44. Low expression of CD11b and CD45
[19] in PB-MCS allows us to exclude leukocyte contamination, including
monocytes. Also PB-MSC expressed detectable levels of IL-17 receptor
(Fig. 1). Our results demonstrated that IL-17 stimulated in vitro migra-
tion and mobilization of PB-MSCs, determined by wound healing and
Boyden chamber-based cell migration, as well as that both responses
were reverted by using anti-IL-17 antibody, indicating the speciﬁcity
andmain role of IL-17 on PB-MSCmotility. In addition, IL-17 stimulated
cell mobilization from the three dimensional collagen drops, which
indicated that IL-17 enhances the capacity of PB-MSCs to move from
extracellular matrix network (Fig. 2). Moreover, this ﬁnding also impli-
cates the possibility of extracellular matrix degradation by proteolytic
mechanism. In that way, we observed that IL-17 induced the expression
of urokinase type plasminogen activator in PB-MSC, mainly by activat-
ing ERK1,2 MAPK, as well as that the uPA increased expression was
necessary for the IL-17-induced cell migration (Figs. 3 and 4). Among
several factors regulating pathophysiological processes required during
tissue remodeling after injury, important roles for the multifunctional
uPA system have been acknowledged [33]. By binding to its cellular
receptor uPA mediates the conversion of plasminogen to plasmin andF-acn
γ-tub
α-tub
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Fig. 6. IL-17 induces cell polarization and uPA cell protrusions localization. (A) IL-17 induces P
ERK1,2-dependentway. Cells were subjected tomigrate in thewound-healing assay in the prese
After being ﬁxed, cells were labeled with phalloidin–TRITC for F-actin (red), with gamma-tub
nucleus. Cells in the edge of the “wound”were photographed, in order to detect migratory cells
(B) PB-MSC treated as above were immune-stained against uPA (green) andwith DAPI (blue) f
with PD98059 (25 μM)without or with IL-17; e and f cells with BC11 treatment (50 μM)witho
(b). Magniﬁcation 400× and scale bar: 50 μm. Representative results from at least three indepthereby produces a ﬁne tune regulated cell surface proteolysis in
space and time, facilitating cells to migrate across extracellular matrix
barrier [34]. Besides, it is known that independent of proteolytic
processes uPA–uPAR axis regulates migration, adhesion, proliferation,
and differentiation of various cell types in tissue regeneration through
activation of an intracellular signaling network [35]. Recently, it has
been reported that by binding to its receptor uPA enhances cell migra-
tion and mobilization from bone marrow, contributing to hMSC migra-
tion into wounded tissue and thus to tissue regeneration. Also, it has
been shown that uPA plays roles in tropism of MSCs to solid tumors,
as well as that the expression of uPA by MSCs themselves increases
MSC migration toward tumors [13,14,28,36,37]. Our data suggested
that IL-17, produced within damaged tissue, may increase MSC mobili-
zation andmigration by inducing uPA expression.MSCs are also capable
to express other types of extracellularmatrix proteinases such asmatrix
metalloproteinase MMP2 and membrane type1 MMP (MMP14) [38],
and MMP2, but not MMP9, was shown to play a role in the migration
of MSCs [39]. However, although the inhibition of MMPs by doxycycline
indicated some role in basal cell migration (Fig. 4A), our results demon-
strated that IL-17 does not modify MMP2 and MMP14 expressions in
PB-MSCs, pointing that IL-17-mediated uPA expression seems to be
critical for the IL-17-induced PB-MSC migration. Additionally, although
in several cell types IL-17 was shown to induce MMP9 [20], neither de-
tectable transcript nor activity for MMP9 was demonstrated in IL-17-
treated PB-MSC.+ +
+ -
- +
B-MSC actin cytoskeleton reorganization and cell polarization in wound healing assay in a
nce or absence of 50 ng/ml of IL-17, without orwith 50 μMBC11or 25 μMPD98059 for 6 h.
ulin antibody for MTOC (in green and indicated by arrows) and with DAPI (blue) for the
. Scale bar for γ- andα-tubulin: 50 μm, and for F-actin 20 μm. 400× and 630× respectively.
or the nucleus. a and b cells without orwith IL-17 treatment (5 ng/ml); c and d cell treated
ut or with IL-17. Zoom indicated uPA localization in cell protrusion under IL-17 treatment
endent determinations are shown.
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actin cytoskeleton and polarization of tubulin network, mainly by a
ﬁne regulated and coordinated localization of MTOC [22,40]. We ob-
served that IL-17 induced actin reorganization with accumulation of
cell lamellipodia, and increased MTOC perinuclear location toward the
wound edge concomitantly with profound changes in tubulin cytoskel-
eton (Fig. 6). These effectsweremediated by ERK1,2MAPK since the use
of speciﬁc inhibitor disabled cells to respond to IL-17 through changes
in cell cytoskeleton. Also, urokinase activity inhibition revoked the IL-
17-induced actin rearrangement, although it did not signiﬁcantly affect
cell polarization. One possible explanation regarding this observation is
that the inhibitor used (BC11) affects uPA activity and does not interfere
with its interaction with the receptor, and inhibited uPA activity may
trigger intracellular signal necessary for cell polarization. In addition,
IL-17 provoked an accumulation of uPA in PB-MCS cell protrusions,
which can contribute to the increment of cell migration. The underlying
mechanism by which IL-17 induces actin cytoskeleton and MTOC rear-
rangement to increase cell migration has not been elucidated yet. One
plausible mechanism is that IL-17 in MSCs may regulate Rho GTPase
family proteins, which are critical regulators of cell migration and
polarization, since RhoA and Rac1 are required for stress ﬁbers and
cell protrusion of lamellipodia, respectively, and Cdc42 for ﬁlopodia
and cell polarity [40,41]. This speculation can be supported by the
previous studies indicating IL-17 activation of Rac1 to induce cell
migration, and of Rho expression and RhoA-kinase activity in endothe-
lial cells [42,43]. Nonetheless, further studies are necessary to elucidate
the requirement of Rho proteins for IL-17-inducedmigration and polar-
ization of PB-MSC.
Both exogenously and endogenous circulating MSCs are known to
preferentially engraft at site of inﬂammation in vivo [44]. MSCs migrate
across the endothelial barrier to exit from circulation in response to sig-
nals, such as growth factors, cytokines and chemokines, produced by in-
ﬂamed tissues. These signals may regulate the function of MSC by
promoting pathogen clearance, suppression of inﬂammation and tissue
regeneration [1,29]. However, the process and underlying mechanisma c
db
(B)
Fig. 6 (coby which PB-MSCmigrate across endothelium toward to the sites of in-
ﬂammation remained unclear. In addition, although inﬂammatory cyto-
kines may stimulate MSC transendothelial migration [44], the role of IL-
17 is unknown. Here, we demonstrated that IL-17 pre-treatment of ei-
ther MSC or EC increased cell–cell adhesion, indicating that both MSCs
and ECs are IL-17's target cells. Moreover, IL-17 used as chemotactic fac-
tor, increased MSC transendothelial migration in an uPA-dependent
way (Fig. 7B). uPA has been involved in vivo in paracellular transmigra-
tion of neutrophils [45], and is plausible to speculate that uPAmay have
similar function in MSCs. By incrementing uPA, IL-17 may increase the
cleavage of endothelial junctions, aswell as by proteolytically degrading
the perivenular basement membrane to increase endothelial perme-
ability. Intriguingly, it has been recently reported thatMSCs canmigrate
through endothelial barrier also by transcellular mechanism in associa-
tion with VCAM-1-enriched “transmigratory cups” [44], suggesting a
dynamic cell–cell interaction which may actively participate in acceler-
ation of the MSC transendothelial migration to damaged tissue. In the
future studies, it would beworthy to determinewhether IL-17may reg-
ulate MSC transcellular migration in the endothelium by regulation of
uPA expression. In association with TNF-a, IL-17 has also been shown
to affect endothelial cell activation and to increase neutrophil transmi-
gration and the expression of adhesion molecules and chemokines in
HUVECs, suggesting that IL-17 induces endothelial inﬂammation by fa-
cilitating cell trans-endothelial migration [46,47].
After crossing endothelial cell barrier MSCs interact with sub-
endothelial extracellular matrix [25] and eventually induce the
degradation of protein barrier to move toward inﬂamed tissue.
Endothelial cells are known to highly produce ﬁbronectin, and we
determined that the IL-17 treatment of PB-MSCs increased cell
adhesion to puriﬁed ﬁbronectin in uPA-dependent fashion (Fig. 7D).
uPA–uPAR interaction with integrin alpha5-beta1, the main ﬁbronectin
receptor, is known to modulate integrin-dependent cell adhesion to
extracellular matrix, and these interactions actively participate in
proteolytic regulation of invasive cell migration [48,49]. Still, we cannot
exclude other mechanisms such as an increment of integrin receptorf
e
ntinued).
442 J. Krstić et al. / Biochimica et Biophysica Acta 1853 (2015) 431–444expression by IL-17. Our results, obtained by using uPA inhibitor and
anti-uPA blocking antibody, suggest that uPA activity and its
interaction with cell surface, mediate the capability of IL-17 to increase
PB-MSC adhesion to ﬁbronectin.
Abnormal IL-17 expression has been implicated with inﬂammatory
pathology in the setting of autoimmune diseases, and IL-17 depletion
has already been adopted as a therapeutic strategy and is currently
being tested in clinical trials for several human autoimmune diseases
[47]. Our in vitro data suggested that IL-17 can be a recruitment signal
for PB-MSCs to migrate and engraft into inﬂamed tissue. Additionally,
as it is believed that MSCs are not spontaneously immunosuppressive,
but require ‘licensing’ or activation to exert their immunosuppressive
effects [1], we can speculate that IL-17 may also modulate MSC
immunomodulatory capacities. However, MSCs themselves seem to
reduce the capacity of Th1 and Th17 cells to produce interferon-γ
and IL-17, respectively [50]. Therefore, high IL-17 levels in damaged
tissue may serve as a signal for MSC recruitment, which in turn may
regulate IL-17 production acting as a negative feedback to control
excessive inﬂammation.
Intriguingly, previous work of our laboratory demonstrated that IL-17
inhibited uPA expression concomitantly with inhibition of myoblast dif-
ferentiation of C2C12 myoblasts [18]. If we assume that IL-17 could act
as PB-MSC tropic signal, engrafted MSCs may in turn regulate thePKH26
DAPI
MERGE
0
0.5
1
1.5
2
2.5 *
(A)
Fo
ld
 in
cr
ea
se
 o
ve
r c
on
tro
l
IL-17  treated
PBMSC
- + -
IL-17 treated 
EC
- - +
Fig. 7. IL-17 stimulates PB-MSC adhesion and transmigration on endothelial monolayer, and
labeled with PKH26 Red Fluorescent reagent were subjected to adhesion assay on endothelial
monolayer without IL-17 treatment; gray bar corresponds to PB-MSCs pretreated with IL-17 (
PB-MSC adhesion on endothelial cell monolayer pretreated with IL-17 (50 ng/ml, 24 h). Pho
monolayer for each treatment. Magniﬁcation 200× and scale bar: 200 μm. Representative resul
difference from the control: *p b 0.05. (B) PB-MSC transmigration across endothelial cellmonola
across endothelial cells seeded in the upper compartment of transwell insert, and IL-17 (50 ng
BC11 (50 μM)was added in both compartments. Transmigrating ﬂuorescent labeled cells were
means ± SEM from at least three independent determinations are shown. Signiﬁcant differen
Endothelial cell cultures in rounded glasses were subjected to immune-staining to ﬁbronect
50 μm. (D) PB-MSC ﬁbronectin adhesion. Cells were pretreated with IL-17 (50 ng/ml, 24 h) a
or absence of uPA inhibitor BC11 or uPA blocking antibody. Representative results as means ±
from the control: *p b 0.05. Results are representative of three independent experiments.enhanced IL-17 expression in the muscle microenvironment, which has
been observed in inﬂammatory myopathies [15], restoring the level of
myoblast expressing uPA and allowingmuscle regeneration after injuries.
Nonetheless, further studies are necessary to determine if PB-MSCs may
regulate IL-17 expression and function in inﬂammatory myopathies.
4.1. Conclusion
IL-17 increases in vitro PB-MSC migration and endothelial barrier
transmigration by inducing uPA expression through ERK1,2 MAPK
activation. These data allow us to better understand the effect of IL-17
on PB-MSCmigration, and point to IL-17 as one of the signals implicated
in MSC recruitment to damaged tissue to enhance regulation of inﬂam-
mation and tissue regeneration.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.11.025.
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